Lupin gets UK marketing authorisation for Luforbec 100/6 µg pMDI EP News Bureau Jun 14, 2021 Luforbec 100/6 µg pMDI is indicated for regular treatment of asthma and for the symptomatic treatment of patients with severe COPD
